secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2023-02-03T23:59:59+00:00
Accession:  0001628280-23-002145
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience Q1 FY2023 revenue $54.2M (+29% YoY), net loss narrows
----------------------------------------------------------------------

- Revenue $54.2M, up 29% YoY; orders $64.7M, up 30% YoY.
- Net loss of $41.8M ($0.74/share) improved from $45.6M ($0.91/share) YoY.
- Cash and investments $438.7M; first products shipped from Wilsonville Factory of the Future.
- Customer count 2,060 (up from ~1,800); gene shipments ~134,000 (vs ~125,000).
- Launched NGS panels for rare disease; Astellas collaboration; biopharma partners at 278 with 95 active programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/0001628280-23-002145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/twist-20230203.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer